IL18
Interleukin-18
As of the edition of 20 October 2026, IL18 (interleukin-18, UniProt Q14116) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14116
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 20
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Digestive system; Bones, joints and muscles; Heart and blood vessels; Blood and lymph; Cancer
- Registered trials of its drugs
- 18
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| GSK-1070806 | Active | Phase 2 | none listed |
| Camoteskimab | Active | Phase 2 | none listed |
| Tadekinig alfa | Active | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 5 |
| Total on the list | 5 |